Latest News - Thermo Fisher Scientific
Top Corporates Hub
Thermo Fisher Scientific
Delta Air, Target, Thermo Fisher Scientific And A Financial Stock On CNBC’s ‘Final Trades’
26.08.2026 07:11
Experts recommend Delta, Thermo Fisher, Target, and Interactive Brokers Group, Inc. due to strong earnings and guidance.
Envetec Appoints Patrick S. Jones as Independent Director
14.08.2026 07:00
Senior Thermo Fisher Scientific executive brings nearly 30 years of healthcare and commercial leadership to support Envetec’s global expansion Patrick S. Jones Patrick S. Jones, President of Thermo Fisher Scientific’s Clinical Diagnostics Division and independent director of Envetec Sustainable Technologies BIRDHILL, Ireland, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Envetec Sustainable Technologies Limited (Envetec), a leading sustainability innovator in clean technology for healthcare and life science
Non-Viral Transfection Reagents Market Report (3rd Edition) by Type of Non-Viral Transfection Method, Application Area, End-User & Region, Featuring Bio-Rad, MaxCyte, MilliporeSigma, Thermo Fisher Scientific
11.08.2026 08:45
Dublin, Aug. 11, 2026 (GLOBE NEWSWIRE) -- The "Non-Viral Transfection Reagents Market (3rd Edition) by Type of Non-Viral Transfection Method, Application Area, End-User and Geographical Regions-Trends and Forecast Till 2035" has been added to ResearchAndMarkets.com's offering. The global non-viral transfection reagents market is projected to increase from USD 0.89 billion in 2026 to USD 2.01 billion by 2035, expanding at a compound annual growth rate of 9.5% during the forecast period. Market gr
Non-Viral Transfection Reagents Market Report (3rd Edition) by Type of Non-Viral Transfection Method, Application Area, End-User & Region, Featuring Bio-Rad, MaxCyte, MilliporeSigma, Thermo Fisher Scientific
11.08.2026 08:45
Dublin, Aug. 11, 2026 (GLOBE NEWSWIRE) -- The "Non-Viral Transfection Reagents Market (3rd Edition) by Type of Non-Viral Transfection Method, Application Area, End-User and Geographical Regions-Trends and Forecast Till 2035" has been added to ResearchAndMarkets.com's offering. The global non-viral transfection reagents market is projected to increase from USD 0.89 billion in 2026 to USD 2.01 billion by 2035, expanding at a compound annual growth rate of 9.5% during the forecast period. Market gr
Beat the Market Like Zacks: Aveanna, FactSet, Shopify in Focus
10.08.2026 12:34
AVAH, FDS and SHOP lead Zacks' recent standouts, with several picks posting strong gains versus the S&P 500.
Thermo Fisher (TMO) vs Danaher (DHR): Which Life Sciences Stock Looks Better Positioned?
10.08.2026 00:01
Thermo Fisher Scientific Inc. (NYSE:TMO) and Danaher Corporation (NYSE:DHR) are two of the world’s largest life sciences tools companies, making them natural competitors for investors looking to capitalize on a recovery in pharmaceutical and biotechnology research spending. Both companies delivered better-than-expected second-quarter results, but while Thermo Fisher (NYSE:TMO) raised guidance on broad-based demand improvement, Danaher’s […]
Labcorp Stock Jumps 14% in a Month as Growth Meets Rich Valuation
07.08.2026 14:36
LH shares surged 14% in a month as stronger earnings, margin gains and growth collide with a valuation above the company's five-year median.
[Latest] Global Deep Eutectic Solvents Market Size/Share Worth USD 735.89 Million by 2034 at a 15.27% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
05.08.2026 19:30
[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Deep Eutectic Solvents Market size & share revenue was valued at approximately USD 177.64 Million in 2024 and is expected to reach USD 204.77 Million in 2025 and is expected to reach around USD 735.89 Million by 2034, at a CAGR of 15.27% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Proionic GmbH, Iol
Weak Growth In Its Primary Market Continues To Weigh Heavily On Bruker Shares
05.08.2026 11:57
Bruker Corporation faces ongoing headwinds from weak academic/government funding that has compressed growth. Read more on BRKR stock here.
Analysts Appear Bullish on Thermo Fisher (TMO): Is The Stock Really a Buy After Earnings?
31.07.2026 19:09
Thermo Fisher Scientific Inc. (NYSE:TMO) recently announced strong fiscal Q2 2026 results, with revenue growing 10% to $11.99 billion, GAAP diluted EPS rising 9% to $4.68, and adjusted EPS growing 13% to $6.03. The results prompted several analysts to raise their price targets, but after the post-earnings rally, investors must decide whether the recovery story […]
How Thermo Fisher Is Riding Bioproduction and AI-Led Growth Trends
31.07.2026 13:20
TMO is expanding bioproduction, AI tools and clinical data capabilities, but execution will be key as competition intensifies.
Thermo Fisher Scientific's Strong Q2 Not Enough to 'Meaningfully' Change H2 Outlook, RBC Says
24.07.2026 16:52
Thermo Fisher Scientific's (TMO) broad-based improvement in Q2 is not enough to "meaningfully" chang
TMO Q2 Deep Dive: Broad-Based End Market Growth and Strategic Portfolio Moves
24.07.2026 14:09
Life sciences company Thermo Fisher (NYSE:TMO) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 10.5% year on year to $11.99 billion. Its non-GAAP profit of $6.03 per share was 5.6% above analysts’ consensus estimates.
Reading Between The Lines Of DHR's Latest Call
24.07.2026 12:23
Danaher's latest earnings call saw analysts repeatedly test one sore spot in an otherwise solid quarter, and management's answers reveal the key risk for investors now.
Thermo Fisher raises 2026 outlook after 10% growth in Q2
24.07.2026 11:25
Thermo’s Q2 performance was driven by its laboratory products and biopharma services business with profits around $6.69bn equating to a 12% uptick YoY.
Thermo Fisher (TMO) Lands ImmuPharma Kapiglucagon Diabetes Manufacturing Role
24.07.2026 09:08
Thermo Fisher Scientific (NYSE:TMO) has been selected by ImmuPharma as the key drug product and contract development manufacturer for its Kapiglucagon diabetes treatment program. The partnership covers development and manufacturing support for Kapiglucagon, an experimental therapy aimed at addressing diabetes. This agreement adds a new project to Thermo Fisher Scientific’s pharmaceutical services portfolio, focused on complex drug development work. For investors tracking Thermo Fisher...
Thermo Fisher (TMO) Climbs 8.7% on Solid Earnings, Price Target Upgrades
24.07.2026 03:05
Thermo Fisher Scientific Inc. (NYSE:TMO) saw its share prices increase by 8.71 percent on Thursday to close at $572.32 apiece, as investors took heart from the strong earnings performance and a series of price target upgrades for its stock. In the second quarter of the year, the company grew its net income by 7 percent […]
Thermo Fisher Scientific Q2 Earnings Call Highlights
24.07.2026 02:05
Thermo Fisher Scientific (NYSE:TMO) reported stronger-than-expected second-quarter 2026 results and raised its full-year outlook, citing improving customer activity across end markets, broad-based growth and contributions from recent acquisitions. Chairman and Chief Executive Officer Marc Casper sa
TMO Q2 2026 Earnings Call Transcript
24.07.2026 00:29
Organic revenue beat guidance at 5% as pharma and biotech activity strengthened.
Cyclosporiasis: Investing In Biosecurity
23.07.2026 02:05
The global food safety testing market is projected to grow from $28.1 billion in 2026 to $52.9 billion by 2034, driving structural growth for the HTEC index.